Seroprevalence of Anti-SARS-CoV-2 IgG Antibodies in Healthcare Personnel in El Salvador Prior to Vaccination Campaigns.

COVID-19, caused by the SARS-CoV-2 virus, is a highly pathogenic emerging infectious disease. Healthcare personnel (HCP) are presumably at higher risk of acquiring emerging infections because of occupational exposure. The prevalence of COVID-19 in HCP is unknown, particularly in low- to middle-income countries like El Salvador. The goal of this study was to determine the seroprevalence of anti-SARS-CoV-2 antibodies among HCP in El Salvador just prior to vaccine rollout in March 2021. We evaluated 2176 participants from a nationally representative sample of national healthcare institutions. We found 40.4% (n = 880) of the study participants were seropositive for anti-spike protein antibodies. Significant factors associated with infection included younger age; living within the central, more populated zone of the country; living in a larger household (≥7 members); household members with COVID-19 or compatible symptoms; and those who worked in auxiliary services (i.e., housekeeping and food services). These findings provide insight into opportunities to mitigate SARS-CoV-2 risk and other emerging respiratory pathogens in HCP in El Salvador.

Safety and immunogenicity of different booster vaccination schemes for COVID-19 used in El Salvador.

Purpose: The effectiveness of coronavirus disease 2019 (COVID-19) vaccination schemes and the combination of vaccines of various platforms for administering booster doses is still being studied since it will depend on the population's response to vaccines. We aimed to evaluate the safety, protection, and immunogenicity of the Salvadorean population's third dose booster COVID-19 vaccine and the potential benefit of homologous vs. heterologous regimens. Materials and Methods: This is an analytical observational cohort study in a population aged 18 to 65 years that was primarily vaccinated with AstraZeneca, Sinovac, or Pfizer/BioNTech. Volunteers were recruited (n=223) and followed up for 3 months after receiving the 3rd vaccine (BNT162b2) as a booster. Adverse reactions were monitored, serum anti-spike immunoglobulin G (IgG) was assessed by chemiluminescence, and a polymerase chain reaction was carried out when subjects developed clinical signs. Results: The cohorts finally included 199 participants, and we observed only mild adverse effects in all cohorts. A significant increase in specific IgG levels was found after the booster dose in all cohorts. The heterologous scheme with Sinovac showed the greatest increase in antibody titer, and a decrease was observed in all participants after 3 months. During the follow-up period, 30 participants showed symptomatology compatible with COVID-19, but only four were laboratory-confirmed and they showed mild clinical signs. Conclusion: These findings indicate that the booster doses used were safe and promoted an immediate increase in immunogenicity, which decreased over time. The heterologous regimen showed stronger immunogenicity compared to the messenger RNA-based homologous scheme.

Síntesis de evidencia. Opciones terapéuticas contra COVID-19 / Evidence synthesis. Therapeutic options against COVID-19

La enfermedad Covid-19, causada por el virus SARS-CoV-2, ha generado la necesidad de desarrollar y reutilizar estrategias terapéuticas que permitan el manejo adecuado y oportuno de esta infección viral. A nivel mundial, cada semana se registran nuevas investigaciones sobre las opciones terapéuticas contra Covid-19 y al momento, solo se han identificado efectos beneficiosos en algunos anticuerpos monoclonales, los glucocorticoides, los corticosteroides inhalados, el tocilizumab y el baricitinib, fundamentados con evidencia de certeza moderada a alta. Este documento tiene como objetivo presentar la evidencia disponible sobre las opciones terapéuticas contra Covid-19 a partir de mayo de 2021. Se presentan dos tablas, la primera, resume la descripción de cada medicamento y la conclusión con respecto a su uso como tratamiento contra el SARS-CoV-2, de acuerdo con la evidencia disponible al momento; en la segunda, se muestra esta evidencia. Se evaluó la calidad de la evidencia de los artículos según los parámetros establecidos por el Joanna Briggs Institute/University of Adelaide de Australia. En el caso de las revisiones sistemáticas y/o meta-análisis, se utilizó la herramienta Amstar 2

The Covid-19 disease, caused by the SARS-CoV-2 virus, has generated the need to develop and reuse therapeutic strategies that allow the adequate and timely management of this viral infection. Globally, new research on therapeutic options against Covid-19 is reported every week and, to date, beneficial effects have only been identified for some monoclonal antibodies, glucocorticoids, inhaled corticosteroids, tocilizumab and baricitinib, supported by evidence from moderate to high certainty. This document aims to present the available evidence on therapeutic options against Covid-19 as of May 2021. Two tables are presented, the first, summarizes the description of each drug and the conclusion regarding its use as a treatment against Covid-19. SARS-CoV-2, according to the evidence available at the time; in the second, this evidence is shown. The quality of the evidence of the articles was evaluated according to the parameters established by the Joanna Briggs Institute/University of Adelaide in Australia. In the case of systematic reviews and/or meta-analyses, the Amstar 2 tool was used

Opinión técnica: Uso de vacunas contra COVID-19 en mujeres embarazadas y mujeres que lactan / Technical Opinion: Use of COVID-19 Vaccines in Pregnant and Lactating Women

A nivel mundial las políticas sobre la vacunación contra el Covid-19 durante el embarazo varían ampliamente. Mientras 41 paises recomiendan no hacerlo, 91 paises tienen políticas que permiten que algunas mujeres embarazadas reciban las vacunas. La evidencia sugiere que las mujeres embarazadas tienen mayor riesgo de desarrollar COVID-19 grave.

Globally, policies on vaccinating against Covid-19 during pregnancy vary widely. While 41 countries recommend against doing so, 91 countries have policies that allow some pregnant women to receive the vaccines. Evidence suggests that pregnant women are at higher risk of developing severe COVID-19

Opciones terapéuticas contra el Covid-19 / Therapeutic options against Covid-19

Este documento tiene como objetivo presentar la evidencia disponible sobre las opciones terapeutas contra el Covid-19. Se presentan 2 Tablas, la primera resume la descripción de cada medicamento y la conclusión con respecto a su uso como tratamiento contra el SARS-Covid-2, de acuerdo con la evidencia disponible al momento y en la segunda tabla se muestra esta evidencia

This document aims to present the available evidence on the therapeutic options against Covid-19. Two tables are presented, the first one summarizes the description of each drug and the conclusion regarding its use as a treatment against SARS-Covid-2, according to the evidence available at the time and the second table shows this evidence

Epidemiology of chronic kidney disease in adults of Salvadoran agricultural communities.

INTRODUCTION: In El Salvador, chronic kidney disease is a serious and growing public health problem. Chronic renal failure was the first cause of hospital deaths in men and the fifth in women in 2011. OBJECTIVE: Determine prevalence of CKD, CKD risk factors (traditional and nontraditional) and renal damage markers in the adult population of specific rural areas in El Salvador; measure population distribution of renal function; and identify associated risk factors in CKD patients detected. METHODS: A cross-sectional analytical epidemiological study was conducted based on active screening for chronic kidney disease and risk factors in persons aged ≥18 years during 2009-2011. Epidemiological and clinical data were gathered through personal history, as well as urinalysis for renal and vascular damage markers, determinations of serum creatinine and glucose, and estimation of glomerular filtration rates. Chronic kidney disease cases were confirmed at three months. Multiple logistical regression was used for statistical analysis. RESULTS: Prevalence of chronic kidney disease was 18% (23.9% for men and 13.9% for women) in 2388 persons: 976 men and 1412 women from 1306 families studied. Chronic kidney disease with neither diabetes nor hypertension nor proteinuria ≥1 g/L (51.9%) predominated. Prevalence of chronic renal failure was 11% (17.1% in men and 6.8% in women). Prevalence of renal damage markers was 12.5% (higher in men): microalbuminuria, 6.9%; proteinuria (0.3 g/L), 1.7%; proteinuria (1g/L), 0.6%; proteinuria (2 g/L), 0.4 %; and hematuria, 1.5%. Prevalence of chronic kidney disease risk factors was: diabetes mellitus, 9%; hypertension, 20.9%; family history of chronic kidney disease, 16.5%; family history of diabetes mellitus, 18.5%; family history of hypertension, 30.6%; obesity, 21%; central obesity, 24.9%; NSAID use, 84.2%; smoking, 9.9%; alcohol use, 15%; agricultural occupation, 31.2%; and contact with agrochemicals, 46.7%. Chronic kidney disease was significantly associated with male sex, older age, hypertension, agricultural occupation, family history of chronic kidney disease and contact with the agrochemical methyl parathion. CONCLUSIONS: The results of this study support suggestions from other research that we are facing a new form of kidney disease that could be called agricultural nephropathy.

Clinical characteristics of chronic kidney disease of nontraditional causes in Salvadoran farming communities.

INTRODUCTION: Chronic kidney disease is a serious health problem in El Salvador. Since the 1990s, there has been an increase in cases unassociated with traditional risk factors. It is the second leading cause of death in men aged >18 years. In 2009, it was the first cause of in-hospital death for men and the fifth for women. The disease has not been thoroughly studied. OBJECTIVE: Characterize clinical manifestations (including extrarenal) and pathophysiology of chronic kidney disease of nontraditional causes in Salvadoran farming communities. METHODS: A descriptive clinical study was carried out in 46 participants (36 men, 10 women), identified through chronic kidney disease population screening of 5018 persons. Inclusion criteria were age 18-59 years; chronic kidney disease at stages 2, 3a and 3b, or at 3a and 3b with diabetes or hypertension and without proteinuria; normal fundoscopic exam; no structural abnormalities on renal ultrasound; and HIV-negative. Examinations included social determinants; psychological assessment; clinical exam of organs and systems; hematological and biochemical parameters in blood and urine; urine sediment analysis; markers of renal damage; glomerular and tubular function; and liver, pancreas and lung functions. Renal, prostate and gynecological ultrasound; and Doppler echocardiography and peripheral vascular and renal Doppler ultrasound were performed. RESULTS: Patient distribution by chronic kidney disease stages: 2 (32.6%), 3a (23.9%), 3b (43.5%). Poverty was the leading social determinant observed. Risk factor prevalence: agrochemical exposure (95.7%), agricultural work (78.3%), male sex (78.3%), profuse sweating during work (76.3%), malaria (43.5%), NSAID use (41.3%), hypertension (36.9%), diabetes (4.3%). General symptoms: arthralgia (54.3%), asthenia (52.2%), cramps (45.7%), fainting (30.4). Renal symptoms: nycturia (65.2%), dysuria (39.1%), foamy urine (63%). Markers of renal damage: macroalbuminuria (80.4%), ß2 microglobulin (78.2%), NGAL (26.1%). Renal function: hypermagnesuria (100%), hyperphosphaturia (50%), hypernatriuria (45.7%), hyperkaluria (23.9%), hypercalciuria (17.4%), electrolyte polyuria (43.5%), metabolic alkalosis (45.7%), hyponatremia (47.8%), hypocalcemia (39.1%), hypokalemia (30.4%), hypomagnesemia (19.6%). Imaging: Ultrasound showed fatty liver (93.5%) and vascular Doppler showed tibial artery damage (66.7%). Neurological symptoms: abnormal tendon reflexes (45.6%), Babinski sign and myoclonus (6.5%), sensorineural hearing loss (56.5%). CONCLUSIONS: This chronic kidney disease studied behaves clinically like chronic tubulointerstitial nephropathy, but with systemic manifestations not attributable to kidney disease. While male agricultural workers predominated, women and adolescents were also affected. Findings support a hypothesis of multifactorial etiology with a key role played by nephrotoxic environmental agents.

Chronic kidney disease and associated risk factors in two Salvadoran farming communities, 2012.

INTRODUCTION: Chronic kidney disease is a global pandemic, affecting the majority of countries in the world. Its prevalence is approximately 10% and it is associated mainly with diabetes and high blood pressure. In El Salvador, it is the leading cause of hospital deaths among men. OBJECTIVE: Determine prevalence of chronic kidney disease and its risk factors in two Salvadoran farming communities. METHODS: From March through September 2012, a descriptive cross-sectional study was conducted in two Salvadoran farming communities: Dimas Rodríguez (El Paisnal municipality) and El Jícaro (San Agustín municipality). The research involved both epidemiological and clinical methods. An active search for chronic kidney disease and its risk factors was carried out in the population aged >15 years. House-to-house visits were carried out to take family and individual health histories and gather data on social conditions and risk factors. A physical examination was performed, along with laboratory tests (urinalysis and blood chemistry) to measure renal function and detect markers for renal damage. RESULTS: A total of 223 persons of both sexes were studied. Overall prevalence of chronic kidney disease was 50.2%. Prevalence of chronic renal failure was 16.1%, with slight variations between the sexes. In El Jícaro, 77.3% of participants reported contact with agrochemicals and 76.6% were farmworkers; the respective figures for Dimas Rodríguez were 75.8% and 73.7%. The next most frequently reported risk factor was NSAID use, at 61.7% in El Jícaro and 77.9% in Dimas Rodríguez. CONCLUSIONS: CKD prevalence is alarming in these communities, among both young and old, men and women, independently of occupation. Health services must cope with the increased CKD burden observed, and are challenged to implement preventive strategies.